ClinicalPath (formerly Via Oncology) Publications

Pathways impact on cancer care Pathways impact on cancer care


Going off pathway: Problem or good care?

Clinical oncology pathways (COP) provide decision support and benchmarking against national standards.  Treatment other than COP recommended is appropriate for some cases. There are limited data on the appropriateness of off pathway treatment. This study examines rates and reasons for off pathway treatment in one cancer center. [Abstract].
Edge, Stephen B et al. Going off pathway: Problem or good care? J Clin Oncol 38: 2020 (suppl; abstr 7014)


Use of treatment pathways reduce cost and increase entry into clinical trials in patients with non-small cell lung cancer (NSCLC)

Read this study aimed at determining if there was a significant difference in the overall cost of treatment between NSCLC patients treated on pathway versus off pathway. [Abstract][Related article].
Weese James et al. Use of treatment pathways reduce cost and increase entry into clinical trials in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 38: 2020 (suppl; abstr e21000)

See all

Managing costs with oncology pathways Managing costs with oncology pathways


Effects of rising drug costs on efforts to control overall cost at a large academic cancer center

Value-based payment programs like the Oncology Care Model (OCM) have focused efforts to reduce costly acute care use through improvements in access and coordination. Read about how participation in OCM affected total cost of cancer care at a large academic cancer center. [Abstract]
Adelson K, et al. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. J Clin Oncol 37, 2019 (suppl 27; abstr 2)

Pathways impact on OCM drug cost

An NCI-designated cancer center found drug costs represent a majority of their total costs. To reduce treatment (Tx) variability, they chose to implement pathways. They hypothesized pathway driven Tx standardization would favorably impact total chemotherapy costs at the implementation site - read the results. [Abstract] [Poster].
Pracilio Csik V et al. Pathways Impact on OCM Drug Cost. J Clin Oncol 37, 2019 (suppl 27; abstr 109)

See all

Clinical research and trials Clinical research and trials


Clinical pathways as a platform to support clinical research

Clinical trials are essential to advancing cancer care; however, actual patient accrual rates generally fall well below the Institute of Medicine’s stated goal of 10% of all newly diagnosed patients. Learn how the ClinicalPath clinical pathways decision support tool promotes awareness of locally available clinical trials and provides associated analytics for cancer centers. [Abstract] [Poster].
Ellis PG, Weese JL. Clinical pathways as a platform to support clinical research. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 (ABSTR 2594)

Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR)

Patient enrollment to clinical trials is lower than desired. Even large organizations with extensive research support services have many barriers to recruitment and poor rates of enrollment. Read about the results of ClinicalPath implementation for clinical trial accrual in a multisite, hospital affiliated, community oncology setting. [Abstract] [Poster].
Shamah CJ, Saphner TJ. Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR). J Clin Oncol 34, 2016 (suppl 7S; abstr 167)

See all

Radiation oncology Radiation oncology

Lag time between evidence and guidelines: Can clinical pathways bridge the gap?

The 2018 American Society for Radiation Oncology guidelines state that hypofractionated whole-breast irradiation may be used for early-stage breast cancer regardless of age, although evidence to support this became available years ago. Before guideline publication, an integrated, comprehensive radiation oncology network sought to change their practice pattern  using clinical pathways. [Article] [PubMed].
Rodríguez-Lopéz JL, Ling DC, Heron DE, Beriwal S. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap? JOP. December 2018:JOP.18.00430


A peer review process as part of the implementation of clinical pathways in radiation oncology: Does it improve compliance?

Implementation of a pathway is a collaborative process, requiring the active involvement of physicians. This approach promotes acceptance of pathway recommendations, although a peer review process is necessary to ensure compliance and to capture and approve off-pathway selections. Read this investigation of the peer review process and factors associated with time to completion of peer review. [Report] [PubMed].
Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance? Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.

See all

Precision oncology and biomarkers Precision oncology and biomarkers


Patterns of biomarker testing rates and appropriate use of targeted therapy in the first-line, metastatic non-small cell lung cancer treatment setting

Clinical pathways were used to understand biomarker testing patterns and ensuing first-line treatment decisions for patients with metastatic NSCLC at 7 cancer programs. Among providers using clinical pathways, biomarker testing rates were high and appropriate selection of targeted therapy was observed. [Manuscript].
Mason C et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting. J Clin Pathways 2017 4(1):49-54.

Using clinical pathways to understand biomarker testing patterns

Learn how data from clinical pathways software can be utilized to understand biomarker testing rates among providers, to then generate hypothesis about patterns of care that may include patient parameters, size of network or other factors that can be further analyzed and tested. [Abstract].
Ellis PG et al. Using clinical pathways to understand biomarker testing patterns. J Clin Oncol 35, 2017 (suppl; abstr e18189)

See all